Nano Biosensors for Early Detection of Kidney Disease Biomarkers: From Conventional Markers to Uromodulin-Based Point-of-Care Diagnostics
International Journal of Drug Delivery Technology · 16.11.2026 · 16 (80s)
DOI: 10.25258/ijddt.16.80s.67 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 16.11.2026. Verfasst von Kavita Sharma und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kidney diseases, particularly chronic kidney disease (CKD) and acute kidney injury (AKI), are major global health problems in which early structural injury may precede substantial change in conventional measures of renal function. Serum creatinine, estimated glomerular filtration rate (eGFR), and urinary albumin remain central to clinical assessment, while cystatin C provides complementary information about filtration. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) provide information related to tubular injury. Uromodulin is particularly attractive because it is produced predominantly by renal tubular epithelial cells and may reflect tubular mass and renal parenchymal integrity. Nanobiosensors combine biological recognition with nanoscale materials and transducers to enable sensitive, rapid and miniaturized measurement. Gold nanoparticles, graphene-based materials, carbon nanotubes, MXenes, metal oxides, magnetic nanoparticles and nanozymes can enhance surface area, biomolecule immobilization, electron transfer, catalytic activity and optical responses. Recent kidney-focused studies include impedance-based uromodulin detection, optical-fiber KIM-1 sensing, electrochemical/aptamer NGAL sensing, cystatin-C nanobiosensors, and smartphone-enabled creatinine/albumin systems. This review critically examines kidney biomarkers, nanomaterial-enabled sensing mechanisms, representative recent platforms, analytical performance, sample matrices, point-of-care integration and translational barriers. Particular emphasis is placed on uromodulin as an underexplored target for nanobiosensing and on multiplex platforms combining uromodulin with NGAL, KIM-1, cystatin C, creatinine and albumin. Future systems integrating microfluidics, artificial intelligence, smartphone interfaces and wearable electronics may enable decentralized and personalized kidney monitoring.
Zitieren
APA
Sharma, K., Fiza, B., Sajid, M., Gouri, P., Sharma, M., Dhameja, S., & Aziz, M. (2026). Nano Biosensors for Early Detection of Kidney Disease Biomarkers: From Conventional Markers to Uromodulin-Based Point-of-Care Diagnostics. International Journal of Drug Delivery Technology, 16(80s). https://doi.org/10.25258/ijddt.16.80s.67
Vancouver
Sharma K, Fiza B, Sajid M, Gouri P, Sharma M, Dhameja S, et al. Nano Biosensors for Early Detection of Kidney Disease Biomarkers: From Conventional Markers to Uromodulin-Based Point-of-Care Diagnostics. International Journal of Drug Delivery Technology. 2026;16(80s). doi:10.25258/ijddt.16.80s.67
BibTeX
@article{Sharma2026,
author = {Sharma, Kavita and Fiza, Bushra and Sajid, Mohd and Gouri, Priya and Sharma, Madhu and Dhameja, Shilpa and Aziz, MD},
title = {Nano Biosensors for Early Detection of Kidney Disease Biomarkers: From Conventional Markers to Uromodulin-Based Point-of-Care Diagnostics},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {80s},
doi = {10.25258/ijddt.16.80s.67}
}
EUVIMED